Bridgebio Therapeutics, a leading innovator in drug development, participated in the 43rd annual JP Morgan Healthcare Conference held in San Francisco from January 13 to 17. The company, invited for the first time to present at this prestigious event, provided key updates on its lead drug candidate, BBT-877, a treatment for idiopathic pulmonary fibrosis, which has garnered significant attention from global investors and big pharma companies.

On January 16, CEO Lee Jung-Kyu delivered a presentation during the main session, sharing the company's business outlook and market potential. He emphasized the progress of BBT-877 in its Phase 2 clinical trial, showcasing its competitive safety profile and promising potential for lung function recovery. 

According to the latest data, BBT-877 demonstrated a relatively low incidence of diarrhea, a common side effect seen with standard IPF treatments, which occurred in only 8.5% of patients by the end of December. This suggests that BBT-877 could have a favorable safety profile compared to competing drugs.

Furthermore, the primary efficacy endpoint of BBT-877 in the Phase 2 trial, the change in Forced Vital Capacity, also showed promising results. At the 24-week mark, the mean change in FVC for the treatment group was -44.3 mL, a significantly smaller decrease compared to placebo groups in previous studies, where the decline ranged from -104 to -134 mL. This suggests that BBT-877 may have the potential to not only slow disease progression but also restore lung function in IPF patients.

Bridgebio Therapeutics also unveiled plans for a Phase 3 clinical trial involving more than 1,000 IPF patients, which is expected to begin in the first half of 2026. The study will assess high-dose, low-dose, and placebo groups over a 52-week treatment period, with the company intending to collaborate with global pharmaceutical companies to advance this study.

In addition to the clinical updates, the company reported that discussions with major global pharmaceutical companies about potential licensing deals for BBT-877 are ongoing. Over the past few months, Bridgebio Therapeutics has signed confidentiality agreements with over half of the top 10 global pharmaceutical companies, and detailed discussions on licensing terms, clinical plans, and timelines were held at the conference.

CEO Lee Jung-Kyu expressed confidence, stating, “We felt a strong increase in global interest from major pharmaceutical and biotech companies and investors regarding BBT-877. Upon returning to Korea, we will continue to focus on the successful completion of the Phase 2 trial and expedite the business development negotiations to finalize a global licensing agreement.”

BBT-877 is currently in the final stages of its Phase 2 trial, with topline data expected in April. Given the unmet medical need in the IPF space, where effective treatments with minimal side effects are highly sought after, BBT-877 has the potential to become a key player in this rapidly growing market, attracting significant attention from large pharmaceutical companies.